Activated Therapy

From Self-sufficiency
Jump to: navigation, search


Activated Therapy is a novel, non-toxic approach for the amelioration of cancer. In activated cancer therapy, a non-toxic therapeutic becomes cytopathogenic when activated by an external energy source including ultrasound or red light. The specific activated therapies are referred to as Ultrasound Activated Cancer Therapy (USAT) and Photodynamic Therapy (PDT). When these therapies are used in combination, it is referred to as the SonneLux Protocol or Sonodynamic-Photodynamic Therapy (SPDT).

[1]

Emerging activated therapeutics (sensitizers) that is used with the SonneLux Protocol are non-toxic and have great specificity for malignant tissue. When activated, the sensitizers cause destruction to cancer cells only and do not impact healthy tissue. The efficacy of the SonneLux Protocol is demonstrated most profoundly through results from mouse, zebra fish studies and clinical trials. Further, the mechanism of tumor cell destruction is necrosis instead of apoptosis. A “vaccine” effect has been noted.

[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients over a 4 Year Period J.N. Kenyon, R.J. Fuller and T.J. Lewis. Current Drug Therapy, 2009,4.
  2. Toxicity and Cytopathogenic Properties Toward Human Melanoma Cells of Activated Cancer Therapeutics in Zebra Fish. T. J. Lewis. Integrative Cancer Therapy, March 1, 2010; 9(1): 84 - 92.